Breast Cancer Research and Treatment

, Volume 123, Issue 1, pp 113–124

Cyclin D1 is a direct target of JAG1-mediated Notch signaling in breast cancer

  • Brenda Cohen
  • Mamiko Shimizu
  • Julia Izrailit
  • Nancy F. L. Ng
  • Yuri Buchman
  • James G. Pan
  • Judy Dering
  • Michael Reedijk
Preclinical Study

DOI: 10.1007/s10549-009-0621-9

Cite this article as:
Cohen, B., Shimizu, M., Izrailit, J. et al. Breast Cancer Res Treat (2010) 123: 113. doi:10.1007/s10549-009-0621-9
  • 960 Downloads

Abstract

The Notch ligand, JAG1 is associated with breast cancer recurrence. Herein, we report on a genomics approach to elucidate mechanisms downstream of JAG1 that promote breast cancer growth. In a survey of 46 breast cancer cell lines, we found that triple negative (TN; basal and mesenchymal ER-, PR-, and Her2-negative) lines express JAG1 at significantly higher levels than do HER2+ or luminal (ER+) Her2 cell lines. In contrast to the luminal lines tested (T47D and MCF7), TN breast cancer cell lines (HCC1143 and MDA MB231) display high-level JAG1 expression and growth inhibition with RNA interference-induced JAG1 down-regulation. We used microarray profiling of TN tumor cells transfected with JAG1 siRNA to identify JAG1-regulated genes (P ≤ 0.005; fold change ≥1.5). Among JAG1-regulated genes identified, cyclin D1 was found to be a direct target of NOTCH1 and NOTCH3. We show that JAG1 down-regulation reduces direct binding of Notch to the cyclin D1 promoter, reduced cyclin D1 expression and inhibition of cell cycle progression through the cyclin D1-dependant G1/S checkpoint. Furthermore, we show that cyclin D1 and JAG1 expression correlate in TN breast cancer expression datasets. These data suggest a model whereby JAG1 promotes cyclin D1-mediated proliferation of TN breast cancers.

Keywords

Notch JAG1 Cyclin D1 Triple negative Breast cancer 

Supplementary material

Copyright information

© Springer Science+Business Media, LLC. 2009

Authors and Affiliations

  • Brenda Cohen
    • 1
  • Mamiko Shimizu
    • 1
  • Julia Izrailit
    • 1
    • 2
  • Nancy F. L. Ng
    • 3
  • Yuri Buchman
    • 3
  • James G. Pan
    • 3
  • Judy Dering
    • 4
  • Michael Reedijk
    • 1
    • 2
    • 5
  1. 1.Campbell Family Institute for Breast Cancer ResearchOntario Cancer InstituteTorontoCanada
  2. 2.Department of Medical Biophysics, Faculty of MedicineUniversity of TorontoTorontoCanada
  3. 3.Campbell Family Institute for Breast Cancer ResearchUniversity Health NetworkTorontoCanada
  4. 4.Division of Hematology/Oncology, David Geffen School of MedicineUniversity of California at Los AngelesLos AngelesUSA
  5. 5.Department of Surgical Oncology, Princess Margaret HospitalUniversity Health NetworkTorontoCanada

Personalised recommendations